Technical Analysis for CPRX - Catalyst Pharmaceutical Partners, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Cup with Handle | Other | 0.00% | |
| 20 DMA Resistance | Bearish | 1.81% | |
| Pocket Pivot | Bullish Swing Setup | 1.81% | |
| Cup with Handle | Other | 1.81% | |
| Gapped Up | Strength | 1.81% | |
| Cup with Handle | Other | 4.85% | |
| NR7 | Range Contraction | 4.85% |
| Alert | Time |
|---|---|
| Up 1 ATR | about 10 hours ago |
| Up 3% | about 10 hours ago |
| Up 2% | about 10 hours ago |
| Rose Above 20 DMA | about 11 hours ago |
| Rose Above Previous Day's High | about 11 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Medication Virotherapy Disorders Epilepsy Pharmaceutical Sciences Prescription Drugs Stage Specialty Pharmaceutical Myasthenia Pharmaceutical Partners Treatment Of Epilepsy Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Tourette Syndrome Treatment Of Tourette Syndrome Urological Diseases
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Medication Virotherapy Disorders Epilepsy Pharmaceutical Sciences Prescription Drugs Stage Specialty Pharmaceutical Myasthenia Pharmaceutical Partners Treatment Of Epilepsy Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Tourette Syndrome Treatment Of Tourette Syndrome Urological Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.495 |
| 52 Week Low | 11.56 |
| Average Volume | 1,302,002 |
| 200-Day Moving Average | 14.62 |
| 50-Day Moving Average | 15.59 |
| 20-Day Moving Average | 15.48 |
| 10-Day Moving Average | 15.27 |
| Average True Range | 0.48 |
| RSI (14) | 54.34 |
| ADX | 13.77 |
| +DI | 28.97 |
| -DI | 21.70 |
| Chandelier Exit (Long, 3 ATRs) | 15.16 |
| Chandelier Exit (Short, 3 ATRs) | 16.19 |
| Upper Bollinger Bands | 16.25 |
| Lower Bollinger Band | 14.71 |
| Percent B (%b) | 0.69 |
| BandWidth | 9.95 |
| MACD Line | -0.12 |
| MACD Signal Line | -0.15 |
| MACD Histogram | 0.0275 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.49 | ||||
| Resistance 3 (R3) | 16.48 | 16.22 | 16.37 | ||
| Resistance 2 (R2) | 16.22 | 16.04 | 16.23 | 16.33 | |
| Resistance 1 (R1) | 16.00 | 15.93 | 16.11 | 16.01 | 16.29 |
| Pivot Point | 15.74 | 15.74 | 15.80 | 15.75 | 15.74 |
| Support 1 (S1) | 15.52 | 15.56 | 15.63 | 15.53 | 15.25 |
| Support 2 (S2) | 15.26 | 15.45 | 15.27 | 15.21 | |
| Support 3 (S3) | 15.04 | 15.26 | 15.17 | ||
| Support 4 (S4) | 15.05 |
